The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
Annals of Oncology2017Vol. 28(8), pp. 1934–1941
Citations Over TimeTop 10% of 2017 papers
Jean‐Philippe Foy, Chloé Bertolus, Marie‐Cécile Michallet, Sophie Deneuve, Roberto Incitti, Nathalie Bendriss‐Vermare, Marie Alexandra Albaret, Sandra Ortiz‐Cuaran, Emilie Thomas, Amélie Colombe, C. Py, Nicolas Gadot, Jean‐Marie Michot, J. Fayette, Alain Viari, Benoı̂t Van den Eynde, P. Goudot, Mojgan Devouassoux‐Shisheboran, Alain Puisieux, Christophe Caux, P. Zrounba, Sylvie Lantuéjoul, Pierre Saintigny
Related Papers
- → Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports(2019)40 cited
- → Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence(2017)30 cited
- → PD-L1 ≥ 50% Lung Cancer Refractory to PD-1 Inhibition: The Role of Salvage Chemo-Immunotherapy Combination(2021)7 cited
- → Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors(2023)3 cited
- → P16.05 Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC(2021)